WINDSOR, England, September 10, 2018 /PRNewswire/ --
Macrophage Pharma Limited ('MPL'), a company focused on thediscovery and development of next-generation small molecules aiming to modulate immune responses to combat cancer and other diseases, announced today the formation of an international Scientific Advisory Board (SAB).
The Scientific Advisory Board
The Scientific Advisory Board includes:
On welcoming the members to the SAB, Steven Powell, CEO of Macrophage Pharma, said: "We are delighted to have attracted this stellar group of experts to our Advisory Board. Their collective knowledge and experience in the field of immunology and oncology will be invaluable as we seek to realise the full therapeutic potential of our ESM™ technology in both cancer and non-cancer fields."
About Macrophage Pharma
Macrophage Pharma is developing a highly novel class of small molecule therapeutics which modulate immune responses to combat disease based on its proprietary Esterase Motif Technology™ (ESM™) platform. The Company's novel ESM™ technology platform is designed to deliver small molecule drugs to macrophages in a highly selective manner. The lead p38MAPi programme is focused on a novel macrophage-targeting p38 MAPK inhibitor. Clinical trials are scheduled to start in 2019. The Company's R&D pipeline includes additional programmes with proprietary compounds targeting a number of targets.
The Company was founded by the CRT Pioneer Fund (CPF) and concluded a Series A financing in 2017 with CPF, Aglaia Oncology Fund II, Novo Holdings A/S and M Ventures. Please visit the company website for further information: http://www.macrophagepharma.com
SOURCE Macrophage Pharma
Subscribe to our Free Newsletters!
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...View All